A Chinese biotech just published the first human data for its coronavirus vaccine candidate, supporting further trials




A Chinese biotech just published the first human data for its coronavirus vaccine candidate, supporting further trials
A Chinese biotech just published the first human data for its coronavirus vaccine candidate, supporting further trials  
COMMENTS

More Related News

U.S. awards new $628 million contract to boost output of potential COVID-19 vaccine
U.S. awards new $628 million contract to boost output of potential COVID-19 vaccine
  • US
  • 2020-06-01 11:53:34Z

As drugmakers race to develop vaccines, tests and therapies for COVID-19, the United States is looking to secure manufacturing capacity under its "Operation Warp Speed" program announced in May to accelerate vaccine development. "Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted," Department of Health and Human Services (HHS) Secretary Alex Azar said in a statement. The HHS task order with Emergent falls under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal agency that funds...

Thailand races to create COVID vaccine, eyes possible medical tourism boost
Thailand races to create COVID vaccine, eyes possible medical tourism boost

Momentum is building behind Thailand's push to create its own coronavirus vaccine, with more manpower and resources dedicated to the effort amid hopes it could boost medical tourism. Thai trials of an experimental vaccine using monkeys started last month, one of at least 100 potential vaccines being developed globally. Bionet-Asia, a local firm working with the government and a top Bangkok university, has put all other activities on hold and dedicated 250 personnel and all of its labs, technology and production facilities to developing a COVID-19 vaccine.

Moderna Embarks On Phase 2 Study Of Covid-19 Candidate; Shares Pop 11%
Moderna Embarks On Phase 2 Study Of Covid-19 Candidate; Shares Pop 11%

Moderna Inc. (MRNA) announced that it has started dosing the first patients in a Phase 2 study with its experimental mRNA-1273 vaccine candidate against the novel coronavirus. Shares shot up 11% to $61.50 on Friday.The Phase 2 study, being conducted by Moderna under its own Investigational New Drug (IND) application, seeks to evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. The biotech company plans to enroll 600 healthy participants across two cohorts of adults ages 18-55 years and older adults ages 55 years and above.Earlier this month, Moderna reported "positive" interim clinical data saying that the Phase 1 study of its...

Vaccine and coronavirus skeptics packed into a hotel for a conference over Memorial Day weekend, defying guidelines
Vaccine and coronavirus skeptics packed into a hotel for a conference over Memorial Day weekend, defying guidelines

200 alternative medicine practitioners and followers attended a conference in a North Carolina hotel over Memorial Day weekend, defying guidelines.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Latin America